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Introduction 
The aim of preventing preterm birth is to improve the health of babies by prolonging 
pregnancy. Preterm birth (PTB), or delivery before 37 weeks gestation, affects 7.3 % 
of pregnancies in the UK 1. Around 75% result from spontaneous preterm labour. The 
remaining 25% are induc d for medical reasons are not considered further in this 
article.   
 
Who is at risk?  
Specific obstetric clinical risk factors and / or ultrasound scan findings associated 
with an increased risk of spontaneous PTB are listed in box 1. However these have 
poor predictive value. Women with multiple pregnancy are also at high risk of 
preterm birth, and their management is discussed in supplementary online material. 
 




• *History of mid-trimester loss 
• *History of preterm prelabour rupture of membranes in a previous pregnancy 
• *History of PTB in a previous pregnancy 
• *History of cervical treatment for CIN 
The presence of any of these clinical risk factors can be considered a trigger for 
cervical length screening by transvaginal ultrasound scan. 
Imaging: 
• Short cervix (less than 25mm) on transvaginal ultrasound examination  



































































Appraising the evidence 
Three therapeutic interventions are available for women at risk of spontaneous PTB 
(Table 1).  However, considerable uncertainty exists over the effectiveness of these 
interventions, in part because clinical trials are hard to perform. Large numbers of 
trial participants are needed because the majority of high-risk women will deliver at 
term, even without treatment.  It is both difficult and expensive to include neonatal 
and childhood outcomes in trials, therefore trials mainly focus on rates of preterm 
birth, not longer-term health outcomes of babies. Furthermore, inconsistencies in 
definitions, inclusion criteria and outcomes in studies mean it is difficult to summarise 
trial data in meta-analyses, and difficult to interpret relevance of the findings to 
individual women in the clinic setting. 
 
What is the evidence of uncertainty? 
 




An individual patient data (IPD) meta-analysis (5 RCTs involving 504 women) and a 
systematic review (12 RCTs involving 3328 women) showed that cervical cerclage 
delayed the gestational age at delivery and reduces PTB in women at risk of early 
delivery 7 8. There was no statistically significant difference in perinatal mortality with 
cerclage,
7 8
. The IPD meta-analysis, which only included women with a short cervix 
(25mm), showed a reduction in composite neonatal morbidity in the cerclage group 7. 
However, no reduction in morbidity was seen in the larger meta-analysis of summary 



































































data, where partcipants in the included studies had a more diverse range of risk factors 
for PTB 
8
. For women, higher rates of vaginal discharge, vaginal bleeding, pyrexia, 
and caesarean section were found in those who underwent cerclage 8.  
 
Vaginal Progesterone 
An IPD meta-analysis (5 RCTs involving 775 women and 827 infants) and a 
systematic review (36 RCTs involving 8523 women and 12,515 infants) support 
vaginal progesterone use to reduce PTB in women with singleton pregnancies at risk 
of PTB 
9 10
. The results of both systematic reviews are mainly driven by one RCT in 
which all pregnant women were screened for cervical length with transvaginal 
ultrasound and progesterone given if the cervix was 10-20mm 
11
. It is difficult to 
interpret these data where universal screening of cervical length in pregnancy is 




A large UK based RCT (OPPTIMUM) was published after these systematic reviews 
and the release of NICE guidelines 
13
. OPPTIMUM is the largest RCT of vaginal 
progesterone and the only one powered to include a childhood primary outcome. It 
included women at risk of PTB (Box 1) and found that vaginal progesterone did not 
reduce any of the primary outcomes: PTB, neonatal death or severe morbidity, or the 
childhood neurodevelopment development (standardised cognitive score (Bayley-III)) 
at 2 years of age 13. There were no harms associated with progesterone use 13. 
 
Cervical Pessary 
Two randomised trials of several hundred women have evaluated the Arabin pessary 
with a short cervix on transvaginal ultrasound 
14 15
.  The smaller trial reported a 



































































benefit in using the pessary 14, whilst the larger trial found no statistically significant 
difference in PTB rate between women randomised to cervical pessary and those 
randomized to expectant management 15. 
 
Comparison of treatments to prevent PTB 
As yet there are no reported trials comparing the effectiveness of cervical cerclage, 
progesterone supplementation and cervical pessary against each other when used in 
isolation or in combined management strategies in women at risk of PTB. 
 
Multiple Pregnancies 
Overall there is less evidence regarding management in multiple pregnancies. See 
Table 3 (online) for summary of evidence. 
 
Cervical cerclage 
A systematic review found no evidence that cervical cerclage reduces PTB in women 
with multiple pregnancy 
16
. However, only 128 women with multiple pregnancy were 
included, firm conclusions about benefits and harms cannot be made. 
 
 Vaginal progesterone 
Evidence from an IPD meta-analysis of 1,7345  women with multiple pregnancies 
shows no benefit from vaginal progesterone in this group as a whole 17. However, 
progesterone did reduce poor perinatal outcome in a small subgroup of 116 women 
who had both multiple pregnancy and a short cervix. Further evidence is required to 
confirm this observation 17.  
 




































































Two randomised controlled trials included twin pregnancies with no other risk factors 
for preterm birth and found there was no difference between cervical pessary 
compared to routine care 
18 19
. A third randomised controlled trial, confined to women 
with multiple pregnancy and a short cervix has recently been published, and did show 
a reduction in PTB with a cervical pessary 20.  
 
Is ongoing research likely to provide relevant evidence? 
Clinical trials addressing uncertainties in clinical management of women at risk of 
spontaneous PTB were identified through a search of clinical trials databases (Box 2) 
and are summarized in table 4. Only two of the five identified studies (C-STITCH and 
STOPPIT-2) have primary outcomes focused on mortality or neonatal health, with 
other studies using the surrogate outcome of gestation at delivery.  
 
An individual patient data meta-analysis of vaginal progesterone to prevent preterm 
birth is planned by the US Patient Centred Outcomes Research Initiative 
(http://www.pcori.org), which should help clarify whether progesterone is effective, 
and if so, which women should be offered it. 
 
It is essential that future studies use standard definitions, protocols and core outcomes 
so that data regarding important, but uncommon outcomes  (like neonatal mortality) 
can be readily synthesized and guide decision-making. 
 



































































Box 2: Search Strategy  
  
What should we do in the light of the uncertainty? 
Parents should be aware that a reduction in incidence of early delivery may not 
necessarily translate into improved health in children. 
 
It is reasonable to follow NICE (UK) guidance on the prevention of preterm birth and 
offer cervical cerclage when there has been a previous PTB, midtrimester loss, 
preterm prelabour rupture of membranes or cervical treatment, and the cervix is short 
6
. Alternatively, progesterone may be offered 
6
, however, the OPPTIMUM trial, 
(published after the NICE guideline), showed no benefit of vaginal progesterone in 
this group 
13
. We were unable to find any international guidance relating to prevention 
of preterm birth. 
 
We believe that further evidence is needed before offering the cervical pessary out of 
a research setting 14 15.  
 
In our opinion women with multiple pregnancies should not be offered treatments to 
prevent PTB (except in the context of clinical trials) as no clear benefit has been 
We searched clinical trials databases (www.controlled-trials.com/isrctn/; 
http://clinicaltrials.gov/) and the UKCRN Portfolio database 
(http://public.ukcrn.org.uk/search/) with search terms relating to PTB, miscarriage, 
perinatal mortality and neonatal morbidity. We also had personal communication 
with the Royal College of Obstetricians and Gynaecologists Preterm Birth Clinical 
Study Group. 



































































shown 16-20.    
 
We suggest that clinicians share the uncertainly about PTB and offer women the 
opportunity to participate in relevant clinical trials.  
 
What you need to know 
• The best intervention for prevention of spontaneous PTB in women with risk 
factors is still unclear In women with a singleton pregnancy risk of PTB and a 
short cervix the evidence for use of cervical cerclage is clearer than that for 
progesterone or cervical pessary. 
• Discuss with parents that prevention of pre term delivery may not necessarily 
translate into improved health in children. 
 
BOX 3 Recommendations for future research 
Future research should: 
• Use standard definitions, protocols and core outcomes so that data can be 
meta-analysed.  
• Be adequately powered for important outcomes including neonatal morbidity 
and periatal mortality, rather than surrogate outcomes such as PTB. 
• Include consent to allow follow-up studies so that long term outcomes can be 
determined. 
• Data from trials should be made available for subsequent meta-analysis 
 
 
How patients were involved in the creation of this article 



































































“Which interventions are most effective to predict or prevent PTB?” was the number 
one uncertainty prioritised by the James Lind Alliance PTB Priority Setting 
Partnership, which brings together patients, carers and clinicians in partnership to 
identify and prioritise research questions and uncertainties relating to a healthcare 




1. Gestation-specific Infant Mortality in England and Wales 2014. 
http://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/causesof
death/datasets/gestationspecificinfantmortalityinenglandandwalesreferencetables. 
Accessed 26th July 2016. 
 
2. Chamberlain C, O'Mara-Eves A, Oliver S, et al. Psychosocial interventions for 
supporting women to stop smoking in pregnancy. Cochrane Database Syst Rev 
2013(10):CD001055. 
 
3. Sandall J, Soltani H, Gates S, et al. Midwife-led continuity models versus other 
models of care for childbearing women. Cochrane Database Syst Rev 
2016;4:CD004667. 
 
4. Spong CY. Prediction and prevention of recurrent spontaneous preterm birth. 
Obstet Gynecol 2007;110(2 Pt 1):405-15. 
 
5. Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm 
birth. Lancet 2008;371(9606):75-84. 
 
6. Preterm Labour and Birth: NICE guideline (NG25), 2015. 
 
7. Berghella V, Rafael TJ, Szychowski JM, et al. Cerclage for short cervix on 
ultrasonography in women with singleton gestations and previous preterm birth: a 
meta-analysis. Obstet Gynecol 2011;117(3):663-71. 




































































8. Alfirevic Z, Stampalija T, Roberts D, et al. Cervical stitch (cerclage) for preventing 
preterm birth in singleton pregnancy. The Cochrane database of systematic reviews 
2012;4:CD008991. 
 
9. Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women 
with an asymptomatic sonographic short cervix in the midtrimester decreases preterm 
delivery and neonatal morbidity: a systematic review and metaanalysis of individual 
patient data. Am J Obstet Gynecol 2012;206(2):124 e1-19. 
 
10. Dodd JM, Jones L, Flenady V, et al. Prenatal administration of progesterone for 
preventing preterm birth in women considered to be at risk of preterm birth. The 
Cochrane database of systematic reviews 2013;7:CD004947. 
 
11. Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate 
of preterm birth in women with a sonographic short cervix: a multicenter, 
randomized, double-blind, placebo-controlled trial. Ultrasound in obstetrics & 
gynecology : the official journal of the International Society of Ultrasound in 
Obstetrics and Gynecology 2011;38(1):18-31. 
 
12. Bazian. Screening for Preterm Labour in asymptomatic, low-risk women. External 
review against programme appraisal criteria for the UK National Screening 
Committee (UK NSC): UK National Screening Committee, 2014. 
 
13. Norman JE, Marlow N, Messow CM, et al. Vaginal progesterone prophylaxis for 
preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. 
Lancet 2016. 
 
14. Goya M, Pratcorona L, Merced C, et al. Cervical pessary in pregnant women with 
a short cervix (PECEP): an open-label randomised controlled trial. Lancet 
2012;379(9828):1800-6. 
 
15. Nicolaides KH, Syngelaki A, Poon LC, et al. A Randomized Trial of a Cervical 
Pessary to Prevent Preterm Singleton Birth. N Engl J Med 2016;374(11):1044-52. 




































































16. Rafael TJ, Berghella V, Alfirevic Z. Cervical stitch (cerclage) for preventing 
preterm birth in multiple pregnancy. The Cochrane database of systematic reviews 
2014;9:CD009166. 
 
17. Schuit E, Stock S, Rode L, et al. Effectiveness of progestogens to improve 
perinatal outcome in twin pregnancies: an individual participant data meta-analysis. 
BJOG : an International Journal of Obstetrics and Gynaecology 2014; 122(1):27-37. 
 
18. Liem S, Schuit E, Hegeman M, et al. Cervical pessaries for prevention of preterm 
birth in women with a multiple pregnancy (ProTWIN): a multicentre, open-label 
randomised controlled trial. Lancet 2013;382(9901):1341-9. 
 
19. Nicolaides KH, Syngelaki A, Poon LC, et al. Cervical pessary placement for 
prevention of preterm birth in unselected twin pregnancies: a randomized controlled 
trial. Am J Obstet Gynecol 2016;214(1):3 e1-9. 
 
20. Goya M, de la Calle M, Pratcorona L, et al. Cervical pessary to prevent preterm 
birth in women with twin gestation and sonographic short cervix: a multicenter 
randomized controlled trial (PECEP-Twins). Am J Obstet Gynecol 2016;214(2):145-
52. 
 
21. Crowe S US, Duley L, Oliver S. . Description of a workshop to set research 
priorities in preterm birth. James Lind Alliance 2014. 
 
Contributors 
SJS and KMKI planned the organization, content, and structure of the article. SJS 
performed the literature search and drafted the article, with crucial edits and additions 
from KMKI. Both authors participated in subsequent revisions. KMKI is guarantor. 
 
Disclosure Statement 



































































We have read and understood the BMJ policy on declaration of interests and declare 
the following interests: SJS is an unpaid representative on Scottish Governmental 
Advisory Groups, and a member of the RCOG Preterm Birth Clinical Study Group 
and has received travel expenses to attend meetings relating to these roles. SJS is 
chief investigator and a co-investigator in trials relating to preterm birth funded by 
NIHR HTA, and the institution she works at has also received research funding from 
Sparks, Tommy’s and the British Maternal and Fetal Medicine (BMFMS) Society. 
SJS has been provided with ultrasound equipment and software for use in studies of 
preterm birth research from GE and Philips. SJS has received Honoraria for 
contributing to book chapters, and travel and accommodation expenses as an invited 
speaker at conferences and academic institutions.  KMKI is chief investigator for C-
STICH, funded by NIHR HTA. KMKI receives travel and accommodation expenses 
as an invited speaker at conferences and academic institutions; however, honoraria or 
royalty fees generated from academic activities funds academic activities related to 
women’s health. The authors had no support from any organization for the submitted 
work. The authors grant the publishers a worldwide license.  
 
Acknowledgments  
The authors would like to thank members of the RCOG Preterm birth Clinical Study 
Group for advice on future research recommendations and information on ongoing 
trials. 
 
Licence for Publication 
The Corresponding Author has the right to grant on behalf of all authors and does 
grant on behalf of all authors, an exclusive licence (or non exclusive for government 



































































employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this 
article (if accepted) to be published in BMJ and any other BMJPGL products and 







































































Treatment What is it? Usual Timing  Evidence and Guidance for 
use 
Cervical Cerclage A purse string suture that 
strengthens and tightens 
the cervix. Usually 
inserted under regional 
(spinal) or general 
anaesthesia. 
 
I serted between 12 
and 24 weeks 
gestation, and 
removed at 37 
weeks gestation or 
if there are signs of 
labour before this. 
Current NICE guideline 
recommends offering 
cerclage to women with a 
clinical risk factor (Box 1) 
and a short cervix on 
ultrasound (<25mm) but 
mainly low or moderate 
quality evidence. 
Progesterone supplements Intravaginal progesterone 
is the only formulation 
available in the UK. 
Usually prescribed as 
once daily pessaries. 
Commenced 
between 16 and 22 
weeks gestation, 
and continued to 
34-36 weeks 
gestation. 
Current NICE guideline 
recommends offering 
vaginal progester ne to 
women with a clinical risk 
factor (Box 1) and/or a short 
cervix on ultrasound 
(<25mm) but mainly low or 
moderate quality evidence. 
Cervical Pessary (Arabin) 
 
A silicon ring that sits 
over the cervix and 
works by supporting the 
cervix and tilting it 
posteriorly. No 
anaesthesia or analgesia 
is required for insertion. 
There is only one 
cervical pessary on the 
market – Arabin. 
Inserted between 18 
and 22 weeks 
gestation, and 
removed at 37 
weeks gestation or 
if there are signs of 
labour before this.  
Not reviewed in current 
NICE guideline. 
 
Table 1: Treatment options for preterm birth 
Comment [SS1]: Images for each sent in 
separate file of supplementary material 
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Table 2 























Systematic review and IPD 
level meta-analysis   
(5 trials; 504 women/infants) 
[7] 
Cervical length less 









28.4% vs 41.3% 
RR 0.70 
95% CI 0.55–0.89 




8.8% vs 13.8% 
RR 0.65 
95% CI 0.40–1.07 
(5 trials; n=504) 
Yes 
 
12.8% vs 20.1% 
RR 0.64 
95% CI 0.43-0.96 
(5 trials; n=504) 
Systematic review and meta-
analysis of summary statistics  
(8 trials; 2392 women, 2391 
infants) [8] 
High risk of preterm 










17.6% vs 23.1% 
RR 0.79 
95% CI 0.68-0.93 




8.4% vs 10.7% 
RR 0.78 
95% CI 0.61-1.00 
(8 trials; n=2391) 
No 
 
17.5% vs  23.2% 
RR 0.82  
95% CI 0.61, 1.09 















Systematic review and IPD 
level meta-analysis  
(5 trials; 775 women, 827 
infants) [9] ** 









16.0% vs 27.1% 
RR 0.61  
95% CI 0.47–0.81 
(5 trials; n= 775) 
No 
 
3.4% vs 5.3% 
RR 0.63 
95% CI 0.34-1.18 




9.7% vs 17.3% 
RR, 0.57  
95% CI, 0.40-0.81 
(5 trials; n= 827) 
Systematic review and meta-
analysis of summary statistics 
















3.7%  vs 5.6% 
RR 0.67  
95% CI 0.34- 1.29 
- 
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95% CI 0.10-0.44 
(4 trials; n=454) 
 
(2 trials; n=752) 
Systematic review and meta-
analysis of summary statistics 











20.8% vs 36% 
RR 0.58 
95% CI 0.38-0.87 




RR 0.56  
95% CI 0.27-1.17 
 
(2 trials; n=732)) 
- 
Randomised Control Trial 
(1228 women/infants) [13] 
High risk of PTB 
(history &/or short 
cervix or positive 
fetal fibronectin + 






18% vs 16% 
Adjusted OR 0·86 
 95% CI 0·61-1·22 
No 
 
1% vs 1% 
Unadjusted OR 1.14 
95% CI 0.41-3.17 
No 
 
Adjusted OR 0·62 
10% vs 7% 












Randomised Trial (1 trial; 385 
women/infants) [14] 
High risk of preterm 









6.3% vs 26.8% 
RR 0.24 
95% CI 0.13-0.43 
(1 trial; n=385) 
No 
 
0 vs 0.5% 
RR 0.0 
95% CI [0.0-0.0] 
(1 trial; n=385) 
 
- 









given if cervical length 





12.0% vs 10.8%, 
OR 1.12 
95% CI 0.75 –1.69 
No 
 
3.2% vs 2.4%  
OR 1.38 
95% CI 0.63-3.4 
No 
 
6.7% vs 5.7%,  
OR 1.18 
95% CI 0.69-2.03 
 
Summary data of Systematic Reviews of Randomised Trials of Interventions to Prevent Preterm Birth (PTB) in Women with Risk Factors and 
Singleton Pregnancy.  
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We performed searches in Medline and the Cochrane Libraries using search terms for PTB combined with terms for progesterone, cervical 
pessary, Arabin and cervical cerclage and a filter for systematic reviews of randomized control trials restricted to studies in humans.  
*This review included data from trials of intramuscular 17 alpha hydroxyprogesterone acetate, which is not available in the UK.  Data presented 
here are restricted to those relating to vaginal progesterone. 
** review included some multiple pregnancies  
IPD : Individual patient level data meta-analsysis 
RR: Risk Ratio 
OR: Odds Ratio 
CI: Confidence Interval 
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Table 3 (online only) 























Systematic review and meta-analysis 
of summary statistics (5 trials, 128 
women, 262 infants) [16] 










(4 trials: n = 83) 
No 
 
19.2% vs 9.5%;  
RR 1.74 
95% CI 0.92-3.28 
(5 trials, n =262) 
No 
 
40.4% vs 20.3% 
RR 1.54 
95% CI 0.58 -4.11,  















Systematic review and IPD level meta-
analysis 
(7 trials; 1,735 women, 3470 infants) 
[17] 







26% vs 28% 
RR 0.94 





2% vs 2% 
RR 0.97  
95% CI 0.65-1.4 
(7 trials; n=3470) 
No 
 
13% vs 13% 
RR 0.97 
RR 0.96 
95% CI 0.83–1.1  
(7 trials; n=3470) 
-------------------** 
Short cervix subgroup 
26.8% vs 63.5%; 
RR 0.57 












 Randomised Trial 
(808 women; 1634 infants) 
[18] 






4% vs 4% 
RR 0.83 
95% CU 0.41-1.68 
[1 trial; n=1,634] 
No 
 
13% vs 14% 
RR 0·98, 
95% CI 0·69–1·39 
[1 trial; n=1,634] 
 
Short cervix subgroup 
12% vs 29% 
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RR 0.40 
95% CI 0.19-0.83 
(n=133) 
 
Randomised Trial  (1,180 women; 
2,354 infants)[19] 














2.5% vs. 2.7% 
RR 0.91 
95% CI 0.55-1.49 
No 
10.0 vs. 9.2% 
RR 1.09 
95% CI 0.85-1.41 
 
Short cervix subgroup 
17.1% vs 14.7% 
RR 1.20 
95% CI 0.77-1.89 (n=396) 
 
Randomised Trial  (137 women; 274 
infants) [20] 
Twins and short 
cervix (≤25mm) 

















5.9% vs 9.1% RR 0.64 
95% CI 0.27-1.50 
 
Table 3: Summary data of Systematic Reviews of Randomised Trials of Interventions to Prevent Preterm Birth (PTB) in Women with Risk 
Factors and Multiple Pregnancy.  
We performed searches in Medline and the Cochrane Libraries using search terms for PTB combined with terms for progesterone, cervical 
pessary, Arabin and cervical cerclage and a filter for systematic reviews of randomized control trials restricted to studies in humans.  
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*This review included data from trials of intramuscular 17 alpha hydroxyprogesterone acetate, which is not available in the UK.  Data presented 
here are restricted to those relating to vaginal progesterone. 
IPD : Individual patient level data meta-analsysis 
RR: Risk Ratio 
OR: Odds Ratio 
CI: Confidence Interval 
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Table 4: Ongoing relevant trials 
 
Title 
Setting [Trial Registration or ID] Funder 
Population Intervention Comparator(s) Primary Outcome Comments 
C-STITCH: Cerclage suture Type for an 
Insufficient Cervix and its effect on 
Health outcomes) 
UK Multicentre [ISRCTN15373349] 
NIHR HTA 
Women with singleton 
pregnancy and indication for 










Pregnancy loss rate 
(miscarriage and perinatal 
mortality, defined as any 
still birth or neonatal death 













MAVRIC: A multicentre randomised 
controlled trial of transabdominal versus 
transvaginal cervical cerclage 
UK Multicentre [ISCTRN33404560] 
The Moulton Charitable Foundation 
Women with singleton 
pregnancy and previous 




High or Low 
Vaginal 
Cerclage 






STOPPIT-2: An open randomised trial 
of the Arabin pessary to prevent preterm 
birth in twin pregnancy, with health 
economics and acceptability 
UK Multicentre [ISCTRN02235181] 
NIHR HTA 
Women with multiple 




Standard care Obstetric: Spontaneous 
PTB  <34 weeks. Neonatal: 






SuPPoRT: Stitch, Progesterone or 
Pessary: a Randomised Trial 
UK Multicentre  
[EudraCT 2015-000456-15] 
NIHR Research Fellowship 
Women with singleton 
pregnancy at high risk of 
spontaneous preterm birth 
















ReCAP: Randomised Trial into 
Prevention of Preterm Birth: Feasibility 
Study 
UK 2 Centres [UKCRN ID 18675] 
Women with singleton 
pregnancies at high risk of 
spontaneous preterm birth 











































































 centile) (Feasibility – 
no specified sample size) 
Pessary  
Abbreviations: HTA: Health Technology Assessment, RfPB: Research for Patient Benefit, PTB: Preterm Birth 
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